search
Back to results

A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity

Primary Purpose

Obesity

Status
Completed
Phase
Phase 2
Locations
Japan
Study Type
Interventional
Intervention
LIK066
Placebo
Sponsored by
Novartis Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring Obesity disease, Over weight, T2DM, interventional study, Weight loss

Eligibility Criteria

20 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with obesity disease and inadequately controlled body weight with diet and/or exercise
  • BMI ≥ 25 kg/m^2 combined with at least two obesity-related comorbidities, or BMI ≥ 35 kg/m^2 at least one obesity-related comorbidity
  • Patients with FPG ≥ 110 mg/dL and/or 5.6% ≤ HbA1c ≤ 10.0%, or T2DM with HbA1c ≤ 10.0%
  • Waist circumference at umbilical level ≥ 85 cm for male, ≥ 90 cm for female
  • Visceral fat area ≥ 100 cm^2
  • Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study

Exclusion Criteria:

  • Pregnancy or lactating women
  • Use of pharmacologically active weight-loss medications
  • Bariatric surgery
  • Ketoacidosis, lactic acidosis, hyperosmolar coma
  • Symptomatic genital ingection or urinary tract infection in the 4 weeks prior to screening
  • Gastro-intestinal (GI) disorders associated with chronic diarrhea
  • Congestive heart failure, New York Heart Association (NYHA) class III or IV

Sites / Locations

  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site
  • Novartis Investigative Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

LIK066 2.5 mg

LIK066 10 mg

LIK066 25 mg

LIK066 50 mg

Placebo

Arm Description

Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.

Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.

Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.

Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.

Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.

Outcomes

Primary Outcome Measures

Percentage Change From Baseline in Body Weight at Week 12
The dose-response relationship of LIK066 as measured by percent change from baseline in body weight relative to placebo after 12 weeks of treatment.

Secondary Outcome Measures

Responder Rates According to Percentage Decrease in Body Weight From Baseline to Week 12
The responder rates according to percentage decrease in body weight either ≥ 3%, ≥ 5% or ≥ 10%, from baseline at Week 12, for the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 No Statistical Analysis for >=5% and >=10% was not calculated due to division by zero
Percentage Change From Baseline in Body Weight at Week 12 in Dysglycemic Participants and Participants With Type 2 Diabetes Mellitus (T2DM)
The dose-response relationship for weight loss in dysglycemic participants and participants with T2DM. Percentage change from baseline in body weight at Week 12.
Change From Baseline at Week 12 on Waist Circumference at Umbilical Level
Waist circumference will be measured to the nearest 0.1 cm in a standing position, at the end of a normal expiration, using a tape at the level of umbilicus. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Percentage Change From Baseline at Week 12 on Hemoglobin A1c (HbA1c)
HbA1c will be measured from a blood sample obtained and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Change From Baseline at Week 12 on Fasting Plasma Glucose (FPG)
FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake) at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Change From Baseline at Week 12 on Systolic Blood Pressure (SBP)
After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Change From Baseline at Week 12 on Diastolic Blood Pressure (DBP)
After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, DBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Triglycerides (TG)
Fasting lipid profile (Triglycerides (TG)), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Total Cholesterol
Fasting lipid profile (total cholesterol), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - High Density Lipoprotein (HDL)
Fasting lipid profile (HDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Low Density Lipoprotein (LDL)
Fasting lipid profile (LDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Percent Change From Baseline at Week 12 on High Sensitive C-reactive Protein (hsCRP)
High sensitivity CRP will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Change From Baseline in Uric Acid at Week 12
Uric acid will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Change From Baseline on Urine Albumin at Week 12
Urine albumin will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Change From Baseline on Urine Albumin to Creatinine Ratio at Week 12
Urine albumin to creatinine ratio will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Percent Change From Baseline on Visceral Fat Area (VFA) at Week 12
VFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Percent Change From Baseline on Subcutaneous Fat Area (SFA) at Week 12
SFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Pharmacokinetics - Plasma Trough Concentrations of LIK066
Plasma trough concentrations of LIK066 were measured at Week 12 after daily administrations of LIK066 (2.5, 10, 25 and 50 mg).

Full Information

First Posted
October 22, 2017
Last Updated
December 9, 2020
Sponsor
Novartis Pharmaceuticals
search

1. Study Identification

Unique Protocol Identification Number
NCT03320941
Brief Title
A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity
Official Title
A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 12 Weeks Treatment With 4 Doses of LIK066 Compared to Placebo in Japanese Patients With Obesity Disease
Study Type
Interventional

2. Study Status

Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
December 7, 2017 (Actual)
Primary Completion Date
July 25, 2018 (Actual)
Study Completion Date
July 25, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis Pharmaceuticals

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to evaluate the efficacy, tolerability and safety of LIK066 to support dose selection for Phase 3 development in Japanese adults with obesity disease.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
Obesity disease, Over weight, T2DM, interventional study, Weight loss

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Masking Description
Parallel Assignment
Allocation
Randomized
Enrollment
126 (Actual)

8. Arms, Groups, and Interventions

Arm Title
LIK066 2.5 mg
Arm Type
Experimental
Arm Description
Eligible patients randomized to this arm will receive LIK066 2.5 mg orally daily for 12 weeks.
Arm Title
LIK066 10 mg
Arm Type
Experimental
Arm Description
Eligible patients randomized to this arm will receive LIK066 10 mg orally daily for 12 weeks.
Arm Title
LIK066 25 mg
Arm Type
Experimental
Arm Description
Eligible patients randomized to this arm will receive LIK066 25 mg orally daily for 12 weeks.
Arm Title
LIK066 50 mg
Arm Type
Experimental
Arm Description
Eligible patients randomized to this arm will receive LIK066 50 mg orally daily for 12 weeks.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Eligible patient randomized to this arm will receive LIK066 matching placebo orally daily for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
LIK066
Intervention Description
LIK066 will be supplied in different doses as tablets to be taken orally daily.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo will be supplied as tablets to be taken daily orally.
Primary Outcome Measure Information:
Title
Percentage Change From Baseline in Body Weight at Week 12
Description
The dose-response relationship of LIK066 as measured by percent change from baseline in body weight relative to placebo after 12 weeks of treatment.
Time Frame
Baseline, Week 12
Secondary Outcome Measure Information:
Title
Responder Rates According to Percentage Decrease in Body Weight From Baseline to Week 12
Description
The responder rates according to percentage decrease in body weight either ≥ 3%, ≥ 5% or ≥ 10%, from baseline at Week 12, for the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12 No Statistical Analysis for >=5% and >=10% was not calculated due to division by zero
Time Frame
Baseline, Week 12
Title
Percentage Change From Baseline in Body Weight at Week 12 in Dysglycemic Participants and Participants With Type 2 Diabetes Mellitus (T2DM)
Description
The dose-response relationship for weight loss in dysglycemic participants and participants with T2DM. Percentage change from baseline in body weight at Week 12.
Time Frame
Baseline, Week 12
Title
Change From Baseline at Week 12 on Waist Circumference at Umbilical Level
Description
Waist circumference will be measured to the nearest 0.1 cm in a standing position, at the end of a normal expiration, using a tape at the level of umbilicus. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Percentage Change From Baseline at Week 12 on Hemoglobin A1c (HbA1c)
Description
HbA1c will be measured from a blood sample obtained and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Change From Baseline at Week 12 on Fasting Plasma Glucose (FPG)
Description
FPG will be measured from a blood sample obtained after an overnight fast (at least 8h after last evening food intake) at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Change From Baseline at Week 12 on Systolic Blood Pressure (SBP)
Description
After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, SBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Change From Baseline at Week 12 on Diastolic Blood Pressure (DBP)
Description
After the subject has been sitting for 5 minutes with the back supported and both feet placed on the floor, DBP will be measured three times using the automatic BP monitor and an appropriate size cuff. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Triglycerides (TG)
Description
Fasting lipid profile (Triglycerides (TG)), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Total Cholesterol
Description
Fasting lipid profile (total cholesterol), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - High Density Lipoprotein (HDL)
Description
Fasting lipid profile (HDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Percentage Change From Baseline at Week 12 on Fasting Lipid Profile - Low Density Lipoprotein (LDL)
Description
Fasting lipid profile (LDL), will be measured on blood samples obtained after an overnight fast and analyzed at a central laboratory For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Percent Change From Baseline at Week 12 on High Sensitive C-reactive Protein (hsCRP)
Description
High sensitivity CRP will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Change From Baseline in Uric Acid at Week 12
Description
Uric acid will be measured from a blood sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Change From Baseline on Urine Albumin at Week 12
Description
Urine albumin will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Change From Baseline on Urine Albumin to Creatinine Ratio at Week 12
Description
Urine albumin to creatinine ratio will be measured from urine sample and analyzed at a central laboratory. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Percent Change From Baseline on Visceral Fat Area (VFA) at Week 12
Description
VFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Percent Change From Baseline on Subcutaneous Fat Area (SFA) at Week 12
Description
SFA by CT scan will be measured at visits and evaluated centrally. For the overall population and each of the subgroups (Dysglycemic and Type 2 Diabetes Mellitis (T2DM)) from Baseline to Week 12
Time Frame
Baseline, Week 12
Title
Pharmacokinetics - Plasma Trough Concentrations of LIK066
Description
Plasma trough concentrations of LIK066 were measured at Week 12 after daily administrations of LIK066 (2.5, 10, 25 and 50 mg).
Time Frame
Week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with obesity disease and inadequately controlled body weight with diet and/or exercise BMI ≥ 25 kg/m^2 combined with at least two obesity-related comorbidities, or BMI ≥ 35 kg/m^2 at least one obesity-related comorbidity Patients with FPG ≥ 110 mg/dL and/or 5.6% ≤ HbA1c ≤ 10.0%, or T2DM with HbA1c ≤ 10.0% Waist circumference at umbilical level ≥ 85 cm for male, ≥ 90 cm for female Visceral fat area ≥ 100 cm^2 Agreement to comply with the study-required life-style intervention and treatment during the full duration of the study Exclusion Criteria: Pregnancy or lactating women Use of pharmacologically active weight-loss medications Bariatric surgery Ketoacidosis, lactic acidosis, hyperosmolar coma Symptomatic genital ingection or urinary tract infection in the 4 weeks prior to screening Gastro-intestinal (GI) disorders associated with chronic diarrhea Congestive heart failure, New York Heart Association (NYHA) class III or IV
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
Novartis Investigative Site
City
Matsudo city
State/Province
Chiba
ZIP/Postal Code
271 0077
Country
Japan
Facility Name
Novartis Investigative Site
City
Chikushino-city
State/Province
Fukuoka
ZIP/Postal Code
818-0036
Country
Japan
Facility Name
Novartis Investigative Site
City
Fukuoka-city
State/Province
Fukuoka
ZIP/Postal Code
810-0066
Country
Japan
Facility Name
Novartis Investigative Site
City
Fukuoka-city
State/Province
Fukuoka
ZIP/Postal Code
819-0006
Country
Japan
Facility Name
Novartis Investigative Site
City
Kitakyushu-city
State/Province
Fukuoka
ZIP/Postal Code
807-0857
Country
Japan
Facility Name
Novartis Investigative Site
City
Akashi
State/Province
Hyogo
ZIP/Postal Code
674-0081
Country
Japan
Facility Name
Novartis Investigative Site
City
Kakogawa-city
State/Province
Hyogo
ZIP/Postal Code
675-0101
Country
Japan
Facility Name
Novartis Investigative Site
City
Yokohama-city
State/Province
Kanagawa
ZIP/Postal Code
231-0023
Country
Japan
Facility Name
Novartis Investigative Site
City
Kumamoto City
State/Province
Kumamoto
ZIP/Postal Code
860-0863
Country
Japan
Facility Name
Novartis Investigative Site
City
Kumamoto-city
State/Province
Kumamoto
ZIP/Postal Code
860-8039
Country
Japan
Facility Name
Novartis Investigative Site
City
Kyoto city
State/Province
Kyoto
ZIP/Postal Code
600-8898
Country
Japan
Facility Name
Novartis Investigative Site
City
Kyoto-city
State/Province
Kyoto
ZIP/Postal Code
615-8125
Country
Japan
Facility Name
Novartis Investigative Site
City
Nagasaki city
State/Province
Nagasaki
ZIP/Postal Code
850 0045
Country
Japan
Facility Name
Novartis Investigative Site
City
Higashiosaka-city
State/Province
Osaka
ZIP/Postal Code
577-0802
Country
Japan
Facility Name
Novartis Investigative Site
City
Higashiosaka-city
State/Province
Osaka
ZIP/Postal Code
577-0803
Country
Japan
Facility Name
Novartis Investigative Site
City
Ageo-city
State/Province
Saitama
ZIP/Postal Code
362-8588
Country
Japan
Facility Name
Novartis Investigative Site
City
Kawaguchi-City
State/Province
Saitama
ZIP/Postal Code
332 0021
Country
Japan
Facility Name
Novartis Investigative Site
City
Tokorozawa-city
State/Province
Saitama
ZIP/Postal Code
359-0042
Country
Japan
Facility Name
Novartis Investigative Site
City
Tokorozawa
State/Province
Saitama
Country
Japan
Facility Name
Novartis Investigative Site
City
Hachioji-city
State/Province
Tokyo
ZIP/Postal Code
192-0046
Country
Japan
Facility Name
Novartis Investigative Site
City
Kiyose-city
State/Province
Tokyo
ZIP/Postal Code
204-0021
Country
Japan
Facility Name
Novartis Investigative Site
City
Minato-ku
State/Province
Tokyo
ZIP/Postal Code
108-0075
Country
Japan
Facility Name
Novartis Investigative Site
City
Shinagawa-ku
State/Province
Tokyo
ZIP/Postal Code
141-0032
Country
Japan
Facility Name
Novartis Investigative Site
City
Toshima-ku
State/Province
Tokyo
ZIP/Postal Code
171-0021
Country
Japan

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Citations:
PubMed Identifier
32072763
Citation
Yokote K, Sano M, Tsumiyama I, Keefe D. Dose-dependent reduction in body weight with LIK066 (licogliflozin) treatment in Japanese patients with obesity. Diabetes Obes Metab. 2020 Jul;22(7):1102-1110. doi: 10.1111/dom.14006. Epub 2020 Mar 12.
Results Reference
derived
Links:
URL
https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=432
Description
A Plain Language Trial Summary is available on novartisclinicatrials.com

Learn more about this trial

A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity

We'll reach out to this number within 24 hrs